Results 211 to 220 of about 585,120 (318)

Low-dimensional population dynamics in the brainstem gate REM sleep. [PDF]

open access: yesNat Neurosci
Lozano DE   +6 more
europepmc   +1 more source

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket   +14 more
wiley   +1 more source

Neuronal Microdifferentiation

open access: yesCold Spring Harbor Symposia on Quantitative Biology, 1983
A, Matus, G, Huber, R, Bernhardt
openaire   +2 more sources

Aquaporin‐4 in Narcolepsy Type 1: Investigation of Perivascular Fluid Movement in Sleep Disorders

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Narcolepsy type 1 (NT1) is caused by the loss of hypocretin‐1 leading to excessive daytime sleepiness and cataplexy. Additionally, disrupted nighttime sleep has become an increasingly recognized feature of NT1. As the glymphatic fluid movement has been linked to sleep architecture, we investigated cerebrospinal fluid (CSF) Aquaporin‐4 (AQP4 ...
Jonas Ranke   +5 more
wiley   +1 more source

Algorithm-hardware co-design of neuromorphic networks with dual memory pathways. [PDF]

open access: yesNat Mach Intell
Sun P   +5 more
europepmc   +1 more source

Prodromal Lewy Body Disorder Features in REM Sleep Behavior Disorder With Biomarker‐Defined Synucleinopathy

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Isolated rapid eye movement sleep behavior disorder (iRBD) is a prodromal state for Lewy body disorders and exhibits biological heterogeneity that may influence clinical expression and progression. We examined clinical features in individuals with iRBD and biomarker‐defined synucleinopathy.
Daniel Weintraub   +24 more
wiley   +1 more source

Home - About - Disclaimer - Privacy